AC Immune SA (ACIU)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
May 06, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
AC Immune Research and Development Expense (Quarterly): 16.52M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.52M |
| September 30, 2023 | 14.05M |
| June 30, 2023 | 15.22M |
| March 31, 2023 | 14.98M |
| December 31, 2022 | 15.73M |
| September 30, 2022 | 14.89M |
| June 30, 2022 | 16.26M |
| March 31, 2022 | 16.37M |
| December 31, 2021 | 21.83M |
| September 30, 2021 | 16.47M |
| June 30, 2021 | 15.05M |
| March 31, 2021 | 14.74M |
| December 31, 2020 | 17.65M |
| September 30, 2020 | 16.87M |
| June 30, 2020 | 13.29M |
| March 31, 2020 | 15.72M |
| December 31, 2019 | 14.81M |
| September 30, 2019 | 11.65M |
| Date | Value |
|---|---|
| June 30, 2019 | 12.66M |
| March 31, 2019 | 11.63M |
| December 31, 2018 | 12.18M |
| September 30, 2018 | 11.73M |
| June 30, 2018 | 10.69M |
| March 31, 2018 | 10.62M |
| December 31, 2017 | 10.28M |
| September 30, 2017 | 8.514M |
| June 30, 2017 | 6.941M |
| March 31, 2017 | 7.422M |
| December 31, 2016 | 7.055M |
| September 30, 2016 | 7.888M |
| June 30, 2016 | 5.814M |
| March 31, 2016 | 5.407M |
| December 31, 2015 | 5.753M |
| September 30, 2015 | 4.308M |
| June 30, 2015 | 4.727M |
| March 31, 2015 | 2.874M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.65M
Minimum
Sep 2019
21.83M
Maximum
Dec 2021
15.51M
Average
15.22M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| CRISPR Therapeutics AG | 95.14M |
| Addex Therapeutics Ltd | 0.5126M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 14.50M |
| MoonLake Immunotherapeutics | 8.098M |